Evaluation of Relationship between Treg-FOXP3+ and Breast Cancer

Immunotherapies is novel strategy of breast cancer treatment that can mentionto using of Tcells. T regulatory (Treg) is subset of T cells. It has an importantmarker protein that maenad FoxP3. Various studies have been reported highTreg levels in peripheral blood, lymph nodes and tumor specimens frompatients with breast cancer. Treg may play an important role in breast cancerimmunopathology by suppress activity of both T CD4+ and T CD8+ functionand also FOXP3 has potential to increase risk of chemokine-driven breastcancer metastasis. Based on explained cases, increassing of Treg may cause ofbraest cancer risk or risk of recurrence. According recent studies in the stage IVbreast cancer Tregs increase significantly in comparision to stage I,II,III. TheFOXP3 gene plays a key role in Treg generation, despite its molecularmechanism of function in breast cancer remain controversial. FOXP3 isexpressed in epithelial cells of the normal human breast. Expression of FOXP3is can be abnormal by gene mutation or disregulation in breast cancer. a clearlyassociation was found between intratumoral FOXP3 expression with invasion,size, and vascularity of breast tumor cells. It is present in breast cancer patientswith long-term follow-up and is a significant parameter for disease prognosis ordrug monitoring in both invasive and noninvasive breast tumors that can beassessed in routinely fixed tissues by immunohistochemistry to detect FOXP3positive T cells. Normal level of FOXP3(not increased levels) has also animportant role in controlling oncogenic factors in epithelial of breast cancercells by controlling due to repress expression of a number of genes. these genesare including: ErbB2/HER2, SKP2, LATS2, c-Myc. Finally, Treg depletionmay become successful and novel treatment of breast cancer.